A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117) Meeting Abstract


Authors: Fuchs, C. S.; Tabernero, J.; Al-Batran, S. E.; Chau, I.; Ilson, D. H.; Van Cutsem, E.; Shitara, K.; Ferry, D.; Emig, M.; Vanvoorden, V.; Hsu, Y. Z.; Xu, Y. H.; Sashegyi, A.; Das, M.; Shah, M. A.
Abstract Title: A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117)
Meeting Title: 2016 Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 34
Issue: 4 Suppl.
Meeting Dates: 2016 Jan 21-23
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2016-02-01
Language: English
ACCESSION: WOS:000378109600173
PROVIDER: wos
Notes: Meeting Abstract: TPS178 -- Gastrointestinal Cancers Symposium -- JAN 21-23, 2016 -- San Francisco, CA -- S -- Source: Wos
MSK Authors
  1. David H Ilson
    269 Ilson